Home » CEPHALON DROPS ON SPARLON FDA REJECTION
CEPHALON DROPS ON SPARLON FDA REJECTION
Drug maker Cephalon Inc. said it will end development of a troubled attention deficit disorder treatment after receiving notification from the Food and Drug Administration that it could not approve the drug.
Yahoo Finance
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May